

Artificial Intelligence (AI) and Machine Learning

Businesses adopting artificial intelligence and machine learning technologies and the companies developing them turn to us to navigate regulatory complexities, potential liabilities, and transactional considerations they face on the path to realizing AI's tremendous potential.

We bring together our extensive technical backgrounds and broad range of subject matter experience to help them:

- identify potential risks through data protection impact assessments;
- navigate whether AI's role is categorized as a medical device by the FDA;
- maneuver through ambiguous FDA guidelines related to AI in drug development;
- counsel on the murky landscape of copyright law in connection with generative AI;
- comply with digital communication laws regarding the use of AI systems in content moderation and advertising;
- ensure the use of AI systems is done in an ethical and responsible fashion;
- mitigate risks from contractual, e-discovery, product liability, regulatory, and tort-based claims; and
- complement their businesses and expand into new markets through investments in and acquisitions of sophisticated AI platforms.

From major corporations to emerging growth companies and their investors, we provide this guidance across the full range of AI/ML technologies including:

- fraud detection and digital identity;

Capability Lawyers



Carolyn Zander Alford
New York



John M. Anderson
Atlanta



Lisa M. Dwyer
Washington, D.C.



Amanda J. Klingler
Washington, D.C.



Phyllis B. Sumner
Atlanta



Ronni D. Solomon
Atlanta

- digital health and personalized medicine;
- chatbots;
- e-commerce and marketplace platforms;
- facial/biometric data recognition;
- intelligent robotics;
- autonomous vehicles;
- data set licensing; and more.

Cases & Deals

June 11, 2025

King & Spalding Advised ThreatQuotient in Its Acquisition by Securonix

ServiceNow to Acquire Certain Assets of Bravium Consulting

April 24, 2025

King & Spalding Secures Complete Defense Verdict for Motive in Competitor Patent Case

[VIEW ALL](#)

Insights

ARTICLE

June 12, 2025

5 Open Questions About FDA's AI-Assisted Review Plans

CLIENT ALERT

May 19, 2025

FDA Announces Completion of AI-Assisted Scientific Review Pilot and Deployment of Agency-Wide AI-Assisted Review

ARTICLE

May 1, 2025

FDA Releases Draft Guidance on Submission Recommendations for AI-Enabled Device Software Functions

[VIEW ALL](#)

Events

SPEAKING ENGAGEMENT

June 20, 2025

Kassi Burns to Speak at the State Bar of Texas Annual Meeting

SPEAKING ENGAGEMENT

June 4, 2025

Charly Helleputte to Speak at AI Global Summit

SPEAKING ENGAGEMENT

May 29, 2025

David Mattern and Mikaela Stone to Speak at the 23rd

[VIEW ALL](#)

News

IN THE NEWS

June 10, 2025

Lisa Dwyer explains why the firm is helping clients develop AI tools “for regulatory compliance purposes” as the FDA rapidly starts to employ AI programs

IN THE NEWS

June 5, 2025

Lisa Dwyer, Robert Hudock, Amanda Klingler, Jessica Ringel, Jeffrey Shapiro, Adam Solander and McKenzie Cato’s Client Alert is referenced in a profile on Elsa, the FDA’s new AI tool

PRESS RELEASE

April 7, 2025

King & Spalding Welcomes Data, Privacy and Security Partner Charles-Albert (Charly) Helleputte in Brussels

[VIEW ALL](#)
